High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients

Stefano Cascinu, Ettore Bichisao, Dino Amadori, Vittorio Silingardi, Paolo Giordani, Elisabetta Sansoni, Gabriele Luppi, Vincenzo Catalano, Romina Agostinelli, Giuseppina Catalano

Research output: Contribution to journalArticlepeer-review

Abstract

Thirty-seven colorectal cancer patients with grade 14 diarrhea (NCICTC) caused by chemotherapy with 5-FU-containing regimens, received oral loperamide at the initial dose of 4 mg followed by 4 mg every 8 h (total dose 16 mg/24 h). Twenty-five patients (69%) were diarrhea-free and were considered to be treatment responders. Eight-four percent of the patients with grade 1 or 2 diarrhea achieved a response, but only 52% of those with grade 34 diarrhea. These data seem to suggest that high-dose loperamide is effective in patients with moderate diarrhea and can be regarded as the treatment of choice. The patients with more severe diarrhea did not respond so well, and should, perhaps, be given first-line treatment with more effective drugs, such as somatostatin analogues (e.g., octreotide).

Original languageEnglish
Pages (from-to)65-67
Number of pages3
JournalSupportive Care in Cancer
Volume8
Issue number1
Publication statusPublished - Jan 2000

Keywords

  • 5-Fluorouracil
  • Diarrhea
  • Loperamide

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Fingerprint Dive into the research topics of 'High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients'. Together they form a unique fingerprint.

Cite this